PAQUID

PAQUID
PAQUID

[email protected]
IPSEN France, Novartis Pharma France, CNSA (Caisse Nationale de Solidarité et d’Autonomie), Roche
IPSEN France, Novartis Pharma France, CNSA (Caisse Nationale de Solidarité et d’Autonomie), Roche

Data collection ongoing| Data analysis ongoing| Closed to new patients

French

France

No

https://www.ncbi.nlm.nih.gov/pubmed/?term=PAQUID

Sociodemographic characteristics, lifestyle, medical antecedents, medications, depressive symptomatology and activity limitations were assessed at baseline and each follow-up time. A complete cognitive evaluation with systematic screening for dementia was performed at baseline and each follow-up time.

Yes
Primary endpoint: dementia; secondary endpoint: functional evaluation

Yes – intend to apply for funding

Alzheimer’s disease and other dementias| Parkinson’s disease

Data is held as individual records
No
Data held on computer based records
No
Yes
Apply to PI or co-ordinator at resource| Access independent of collaboration with PI
No policy exists
No

To study cerebral and functional ageing
Population-based cohort
150

1,000-5,000 participants
Examination by a neurologist or a geriatrician
Prospective cohort| Longitudinal
Mainly through the study + link with cancer registry

Yes
Participants free of the disease can be used as controls
01/01/1988
Last follow-up: 2016; however a next follow-up is planned
Data collection ongoing| Data analysis ongoing| Closed to new patients
Only through the study

Data summarised in database

No
No
No
PAQUID
Already possible

Population Cohorts
France
Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders
2016